Ambrx Biopharma Inc.(AMAM) News

Date	Title
Nov 28	Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
Sep 5	Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences